ABT · NYSE · STOCK
Abbott Laboratories (ABT) Stock Analysis
$108.27
52W $81.97 – $137.49
61/100
$187.44B
34.8
0.59
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ABT Bullish or Bearish?
Bullish.
Innellis AI committee rates Abbott Laboratories (ABT) Buy with a composite score of 61/100
, based on 6 analysts with 67% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.59 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.41 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Positive signals support the current rating — low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock. The committee sees sufficient evidence to maintain the constructive view.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 34.6 is moderate-to-rich — Value
- Price-to-book of 4.2x prices in significant intangible value — Value
- EPS declining -61.2% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
61/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 43%
of 192 Healthcare peers
Value Analyst
neutral
47
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 34.6 is moderate-to-rich
Growth Analyst
neutral
48
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -61.2% YoY despite any revenue growth
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 61.4 to 61.4.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
35.3
Neutral
MACD Histogram
-1.199
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$105.50
Resistance
$108.94
Bollinger %B
0.16
Inside Bands
Price vs Moving Averages
EMA 9
$110.52
Below
EMA 21
$110.18
Below
EMA 50
$105.74
Above
EMA 200
$106.48
Above
Fundamental Analysis
Valuation
62
Growth
59
Profitability
72
Financial Health
71
Cash Flow
70
Valuation
P/E Ratio
34.8×
P/B Ratio
3.69×
PEG Ratio
-0.57
Dividend Yield
2.29%
52W High
$137.49
52W Low
$81.97
Quality & Growth
ROE
1251.5%
ROA
752.4%
Gross Margin
5680.4%
Operating Margin
1702.7%
Revenue Growth YoY
—
Debt / Equity
0.64
AI Fundamental Assessment
P/E ratio of 34.8 (rich relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.5%; Return on assets of 7.5%; Net margin of 11.6%; Gross margin of 56.8%; Current ratio of 1.38 (tight short-term liquidity); Debt-to-equity of 0.64; Free cash flow per share is positive (5.00); Most recent quarter beat estimates by 1.4%; EPS growth accelerating (-23.3% -> +13.9% QoQ); Average YoY EPS growth of 4.0%; Analyst estimates falling over recent quarters
Get the Full ABT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →